Mexican contributes to vaccine design for Alzheimer's and Parkinson


Mexico City A group of researchers at Texas University in Galveston, USA, is working on the design of therapeutic vaccines that can be used to administer neurodegenerative diseases such as Alzheimer's and Parkinson.

This scientific team is the Mexican Moros Jair Guerrero mono, who tells in an interview that his role in the project was the generation and purification of conformational monoclonal antibodies to be used in practicinal studies.

Guerrero Muñoz holds a Bachelor's Degree in Chemical Biology from the Autonomous University of Nuevo Leon (UANL), where he also studied a Master's Degree in Molecular Biology and a Doctorate in Morphology with a Neuroscience Orientation.

"Since my PhD studies, I was interested in neurodegenerative diseases and at the end there was the possibility of doing cancer research for John Hopkins Hospital, but I chose to work at the Department of Neurology at the University of Texas in Galveston.

On the functions of vaccines, the Mexican scientist details that they have as a therapeutic target the once-aliomers of proteins that are neural deaths. Due to unknown factors, some proteins have changed their three-dimensional structures to adapt to toxic forms that cause neuronal deaths in diseases such as Alzheimer's and Parkinson. "The antibodies that make the vaccines recognize the toxic structures and bind to them, which makes it easier for them to be removed by the immune system."

As part of the project, the University of Texas has patented the antibodies that Dr. Guerrero Muñoz worked. The investigation was completed by the Practical Studies, which, in vitro tests and in vivo tests, performed with maier models; The next step is to carry it into humans under all the protocols that the authority put on.

"When I left the university, my mentor began to make contact with some pharmacists to make the humanization of the antibodies later perform other tests."

Meanwhile, Dr. Guerrero Muñoz is an academic researcher at the University of Chemical Sciences.

"The vaccine is considered to be admitted into the early stages of neurodegenerative diseases in order to prevent its adversity and damage to the quality of life of the patient.We want to show that it is functional even when the disease has some progress; , It is very important to advance in the study so that it is a preventive method. "

Source link